Apollo Hospitals reports Q4 FY25 net profit of ₹414.50 Cr (+60.41% YoY) and revenue of ₹5,592.20 Cr (+13.11% YoY). EPS at ₹27.10 (+53.34% YoY).
Revenue Growth, Net Profit, EPS, Institutional Holding, ROE. ROCE
YoY Revenue Growth at 13.11%. QoQ Revenue stable.
YoY Net Profit Soars from Rs. 258.40 Crore to Rs. 414.50 Crore, translating to 60.41% Growth.
Substantial Growth in YoY EPS by 53.54%
ROE at 19.09%, ROCE at 17.12%, and ROIC at 12.61%.
Institutional Favorite – FII Holding at 42.74% and DII Holding at 22.29%; FII holding decreased by 2.53%, whereas FII+DII holding decreased by merely 0.21%.
Valuation – Expensive – at a premium valuation.
This is not a Buy/Hold/Sell recommendation.
Standard Warning: Investments in the securities market are subject to market risks. Please read all related documents carefully before investing.
Disclaimer – Ghansham Joshi Prop of GJ’s Techno Funda
Disclosure As Per Securities And Exchange Board Of India (Research Analysts) Regulations, 2014
Know more about the company on Screener.
About the Company – Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, a renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country.
Apollo Hospitals has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models.
BSE: 508869 NSE: APOLLOHOSP
Nice analysis.